Effect of enoxaparin on d-dimer level and survival in hospitalized COVID-19 patients: An observational study

Coronavirus disease 2019 (COVID-19), is caused by Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-2) infection. It is associated with a severe coagulopathy i.e. Venous Thrombo-embolism (VTE), for which optimum strategies ought to be developed for early treatment. D-dimer, a fibrin degradation product is raised in critical COVID-19 pneumonia and increases mortality. Enoxaparin, a low molecular weight heparin, has shown beneficial results in prevention and treatment of VTE. During management of COVID 19 patient with subcutaneous enoxaparin a decrease in D-dimer level is expected primarily because of decreased coagulation leading to decreased fibrin production. It was an observational study with data collected from 86 patients admitted to dedicated COVID hospital, VIMSAR, Burla, Odisha, from April 2022 to August   2022. Medical records of all hospitalized COVID-19 patients with D-dimer   and prescribed enoxaparin (40mg s.c.) were analyzed with due permission from authorities. D-dimer level was evaluated before and after treatment with enoxaparin (on day of admission and day 5). Total 86 case records were analyzed and there was significant reduction in D-dimer level in covid patients after subcutaneous enoxaparin. (z value= -5.265,p value ooo1). Data analysis was done in SPSS software version 21 using a Nonparametric Test i.e.&nbsp